Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Here, we report the results of a phase I/II, single-arm study (UMIN-CTR Clinical Trial Registry
UMIN000002661) assessing the safety (primary endpoint) of G47∆, a triple-mutated …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …

The prognosis of malignant gliomas remains poor, with median survival fewer than 20
months and a 5-year survival rate merely 5%. Their primary location in the central nervous …

Abstract Teserpaturev/G47Δ (Delytact®) is a third-generation (triple-mutated) recombinant
oncolytic herpes simplex virus type 1 being developed by Daiichi Sankyo Co., Ltd. for the …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality
treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields …

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …